Pol JG - Search Results

1

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning.

Pol JG, Atherton MJ, Stephenson KB, Bridle BW, Workenhe ST, Kazdhan N, McGray AR, Wan Y, Kroemer G, Lichty BD. Pol JG, et al. J Immunother Cancer. 2020 Aug;8(2):e000981. doi: 10.1136/jitc-2020-000981. J Immunother Cancer. 2020. PMID: 32792361 Free PMC article.

2

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y. Bridle BW, et al. Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8. Mol Ther. 2013. PMID: 23295947 Free PMC article.

3

Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses.

Zhang L, Bridle BW, Chen L, Pol J, Spaner D, Boudreau JE, Rosen A, Bassett JD, Lichty BD, Bramson JL, Wan Y. Zhang L, et al. Blood. 2013 Mar 28;121(13):2432-9. doi: 10.1182/blood-2012-06-438481. Epub 2013 Jan 16. Blood. 2013. PMID: 23325836 Free article.

4

Panorama from the oncolytic virotherapy summit.

Pol JG, Marguerie M, Arulanandam R, Bell JC, Lichty BD. Pol JG, et al. Mol Ther. 2013 Oct;21(10):1814-8. doi: 10.1038/mt.2013.207. Mol Ther. 2013. PMID: 24081122 Free PMC article. No abstract available.

5

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8⁺ T-cell responses to anticancer vaccines.

Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y. Bridle BW, et al. Oncoimmunology. 2013 Aug 1;2(8):e26013. doi: 10.4161/onci.26013. Epub 2013 Aug 27. Oncoimmunology. 2013. PMID: 24083086 Free PMC article.

6

Maraba virus as a potent oncolytic vaccine vector.

Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD. Pol JG, et al. Mol Ther. 2014 Feb;22(2):420-429. doi: 10.1038/mt.2013.249. Epub 2013 Oct 25. Mol Ther. 2014. PMID: 24322333 Free PMC article.

7

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Workenhe ST, et al. Among authors: pol jg. Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9. Mol Ther. 2014. PMID: 24343053 Free PMC article.

8

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Workenhe ST, et al. Among authors: pol jg. Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19. Cancer Immunol Res. 2013. PMID: 24777969

9

Trial Watch: DNA vaccines for cancer therapy.

Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Pol J, et al. Oncoimmunology. 2014 Jan 1;3(1):e28185. doi: 10.4161/onci.28185. Epub 2014 Apr 1. Oncoimmunology. 2014. PMID: 24800178 Free PMC article. Review.

10

Trial Watch:: Oncolytic viruses for cancer therapy.

Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L. Pol J, et al. Oncoimmunology. 2014 Jun 1;3:e28694. doi: 10.4161/onci.28694. eCollection 2014. Oncoimmunology. 2014. PMID: 25097804 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

97 results

Search Page